背景:肿瘤护理的支付正越来越多地从按服务付费转向基于价值的支付(VBP)。VBP是协议,其中提供者通过与付款人的风险分担安排对总护理成本(TCOC)负责,这些付款人将报销水平与TCOC基准挂钩。肿瘤学生物仿制药可能在管理VBP中的财务风险方面发挥重要作用,例如Medicare的肿瘤学护理模型(OCM),但这方面的研究有限。这项研究的目的是根据MedicareOCM的条款,评估采用生物仿制药对TCOC和肿瘤学提供者财务绩效的影响。
方法:我们使用医疗保险有限数据集(LDS)和医疗保险OCM的方法进行了基于人群的模拟研究。主要结果是由于使用生物仿制药作为参考产品的替代品而导致的每6个月护理事件中TCOC的模拟平均变化。研究人群包括2020年的护理事件,并使用贝伐单抗的参考产品或相应的生物仿制药,利妥昔单抗,曲妥珠单抗,epoetinalfa,filgrastim,或者pegfilgrastim.仅使用参考产品计算每个护理事件的TCOC,并将其与具有相应生物仿制药的TCOC进行比较。该模拟计算了从MedicareLDS研究人群中抽样的100次发作的队列中的TCOC结果,使用10,000次迭代的蒙特卡罗模拟。
结果:在研究期间(从2020年1月至2020年7月开始)在Medicare索赔中确定的总共8281次6个月的肿瘤护理事件中,1586例(19.2%)符合OCM和研究标准并纳入。将模拟方法应用于这些观察到的事件,生物仿制药替代使每集平均TCOC降低1193美元(95%CI583-1840美元)。生物仿制药的成本降低占平均TCOC基准的2.4%,并导致提供者需要向Medicare支付超过TCOC基准的补偿的风险降低了15%。
结论:根据我们使用观察到的医疗保险索赔和OCM标准进行的模拟研究,我们发现,在迄今为止实施的基于价值的最大支付模式的条款下,参考产品的生物仿制药替代可以显著降低事件TCOC并改善供应商的财务绩效.
Payment for oncology care is increasingly moving from fee-for-service to value-based payment (VBP). VBPs are agreements in which providers are held accountable for total cost of care (TCOC) through risk-sharing arrangements with payers that tie reimbursement levels to TCOC benchmarks. Oncology
biosimilars may play an important role in managing financial risk in the VBPs like Medicare\'s Oncology Care Model (OCM), but there has been limited research in this area. The objective of this study is to estimate the impact of biosimilar adoption on TCOC and oncology provider financial performance under the terms of the Medicare OCM.
We conducted a population-based simulation
study using the Medicare Limited Data Set (LDS) and the methodology of Medicare\'s OCM. The primary outcome was the simulated average change in TCOC per 6-month episode of care attributable to use of
biosimilars as an alternative to reference products. The study population consisted of episodes of care in 2020 and using the reference product or corresponding biosimilar for bevacizumab, rituximab, trastuzumab, epoetin alfa, filgrastim, or pegfilgrastim. TCOC was calculated for each episode of care with use of reference products only and compared with TCOC with corresponding
biosimilars. The simulation calculated TCOC outcomes in cohorts of 100 episodes sampled from the Medicare LDS study population using a Monte Carlo simulation with 10,000 iterations.
Among the total of 8281 6-month oncology care episodes identified in the study period (initiating January 2020 to July 2020) in Medicare claims, 1586 (19.2%) episodes met OCM and study criteria and were included. Applying the simulation methods to these observed episodes, biosimilar substitution reduced mean TCOC per episode by $1193 (95% CI $583-1840). The cost reduction from
biosimilars represented 2.4% of the average TCOC benchmark and led to a 15% reduction in the risk of providers needing to pay recoupments to Medicare for exceeding TCOC benchmarks.
On the basis of our simulation study using observed Medicare claims and OCM criteria, we found that biosimilar substitution for reference products can significantly lower episode TCOC and improve provider financial performance under the terms of the largest value-based payment model implemented to date.